<DOC>
	<DOCNO>NCT01510366</DOCNO>
	<brief_summary>Based pre-clinical trial phase 1 phase 2 clinical data principle GCP , objective phase Ⅲ clinical trial evaluate safety immunogenicity Inactivated Poliomyelitis Vaccine make Sabin Strains ( Sabin IPV ) .</brief_summary>
	<brief_title>The Clinical Trial Protocol Inactivated Poliomyelitis Vaccine Made From Sabin Strains ( Sabin IPV )</brief_title>
	<detailed_description>The Sabin IPV manufacture poliovirus type 1 , 2 , 3 Sabin strain Vero cell microcarrier culture 550 liter bioreactors . The virus suspension harvest , ultra-concentrated , purified inactivate formalin . The D Ag content Sabin IPV type 1 30DU , type 2 32DU , type 3 45DU /0.5ml/per dose . Inactivated Poliomyelitis Vaccine ( Salk strain ) manufacture Sanofi Pasteur D Ag content /0.5ml/per dose type 1 40DU , type 2 8DU , type 3 32DU . This randomized , blind phase 3 clinical trial . Total 1200 infant ( age 60 day 90 day ) select , randomize two group ( Sabin IPV Salk IPV , group n=600 ) , infant group vaccinate three dos either Sabin IPV Salk IPV respectively , one month apart .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female , age 60 day 90 day ; Adults , parent ( ) guardians able understand sign inform consent participation ; Participants guardians able attend plan clinical appointment obey follow study instruction ; Infants vaccinate poliovaccine preventive biologicals recent 7 day ; Axillary temperature ≤37℃ . Have medical record participant family allergy , convulsion , fall sickness , encephalopathy psychopathy ; Low platelet bleed disorder allow vaccination muscle ; Have damage low immunological function ; Received blood , plasma immunoglobulin treatment since birth ; Have inborn abnormality , develop obstacle clinical diagnostic serious chronic ( Down Syndrome , diabetes , sickle cell anemia neural GuillainBarre Syndrome ) ; Have doubtful following disease : respiratory system diseases , acute infection active chronic , cardiovascular disease , liver kidney disease , skin disease , HIV . Exclusion Criteria dose 2 3 Have serious anaphylaxis high fever , convulsion first dose ; Have circus Exclusion Criteria Eligible study ; Have serious adverse event relate previous vaccination ; Withdrawal Discontinuance Criteria ; Received necessary interference study drug : immuneinhibition immunestimulating agent ; Vaccinated vaccine（except DTP） ; Stop observation determine investigator owe occur serious adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Inactivated Poliomyelitis Vaccine</keyword>
	<keyword>Sabin Strains</keyword>
	<keyword>poliomyelitis</keyword>
</DOC>